Mark J Rosenblum
CIK 1329154 · Exec VP Finance, CFO · last filed 2025-11-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
2
Total Filings
32
Lifetime Open-Market Net
$110.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Exec VP Finance, CFO | 20,177 | $0.84 | $16.9K | $62.0K | 20 | 2025-11-20 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Chief Financial Officer | 113,774 | — | — | $48.0K | 4 | 2014-02-04 |
Recent Filings · Page 2 of 4
32 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-01-21 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-05 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +7,787 | $5.6K | EDGAR |
| 2021-05-05 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +9,563 | $5.4K | EDGAR |
| 2020-12-04 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-11-05 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | +4,723 | $2.6K | EDGAR |
| 2020-08-18 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Buy (P) | +5,000 | $5.0K | EDGAR |
| 2020-07-16 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-03-25 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-20 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Buy (P) | +2,000 | $1.9K | EDGAR |
| 2020-02-13 | Salarius Pharmaceuticals, Inc. (SLRX) Delisted | Buy (P) | +5,000 | $4.3K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.